Assessing Synopsys (SNPS) Valuation As Fresh Institutional Buying And Converge Conference Optimism Build

Why fresh institutional buying is putting Synopsys (SNPS) on watchlists

Recent filings showing increased Synopsys (SNPS) holdings by Douglas Lane & Associates, Vanguard, Morgan Stanley, BlackRock, and ARK Invest have put the stock back in focus for investors watching semiconductor software exposure.

At the same time, Synopsys is preparing to host its Converge Conference in March. The event is designed to highlight its silicon to systems and AI driven engineering capabilities. Ongoing analyst buy ratings continue to shape sentiment around the name.

See our latest analysis for Synopsys.

Synopsys shares trade at US$501.39 after a 30 day share price return of 5.1% and a 90 day share price return of 7.7%. The 3 year total shareholder return of 40.3% contrasts with a 1 year total shareholder return decline of 8.2%, suggesting long term holders have still seen meaningful gains even as near term sentiment has cooled around recent earnings expectations and the upcoming Converge Conference.

If Synopsys has you thinking more broadly about chip design and AI, this could be a useful moment to scan high growth tech and AI stocks for other potential ideas on your radar.

With the stock at US$501.39, annual revenue of US$7.1b, net income of US$1.3b, and analysts seeing room to US$555.65, the key question is whether Synopsys is still mispriced or if the market is already accounting for future growth.

Most Popular Narrative: 9.8% Undervalued

With Synopsys last closing at $501.39 against a most-followed fair value estimate of $555.65, the current setup hinges on how investors view its silicon to systems story and IP headwinds.

The acquisition and integration of Ansys positions Synopsys as the global leader in engineering solutions from silicon to systems, dramatically expanding its addressable market into sectors like automotive, industrial, and aerospace. This should drive long-term top-line growth as more sophisticated and complex products (especially AI-powered and smart devices) require robust simulation, analysis, and EDA tools.

Read the complete narrative.

Want to see what is baked into that fair value? Revenue, margins and future earnings are all wired into one tight set of assumptions. Curious which levers matter most?

Behind the scenes, the narrative is wiring together expectations for steady earnings growth, faster top line expansion than the wider US market, and a future earnings multiple that stays elevated relative to peers. It is also building in a specific discount rate to bring those projected cash flows back to today, which is where the difference between $501.39 and $555.65 really comes from.

Result: Fair Value of $555.65 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the narrative could easily be tested if prolonged IP segment headwinds or China related export restrictions weigh more heavily on revenue and earnings expectations.

Find out about the key risks to this Synopsys narrative.

Another View: Valuation Through Earnings Multiples

While the fair value narrative points to Synopsys trading 9.8% below a US$555.65 estimate, the earnings multiple story is less forgiving. On a P/E of 71.8x, Synopsys sits well above the US Software industry at 30.8x and peers at 47.1x, and above a fair ratio of 41.4x.

That gap suggests the market already prices in a lot of future execution on AI, Ansys integration and IP recovery, leaving less buffer if those expectations are pushed out. For you, the question is whether this premium feels like justified conviction or stretched optimism.

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Synopsys Narrative

If this view does not quite match your own thinking, or you prefer to work directly off the numbers yourself, you can spin up a custom thesis in just a few minutes and Do it your way

A great starting point for your Synopsys research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Synopsys has sharpened your focus, do not stop here. Broaden your watchlist with fresh angles so you are not missing opportunities elsewhere.

• Target income potential with these 13 dividend stocks with yields > 3% if you want yield to play a bigger role alongside growth names like Synopsys.
• Hunt for potential mispricings by scanning these 873 undervalued stocks based on cash flows where market expectations and cash flow profiles do not always line up.
• Get ahead of emerging themes by checking out these 18 cryptocurrency and blockchain stocks linked to blockchain adoption and digital asset infrastructure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com